Omnicell (NASDAQ:OMCL) EVP Corey Manley Sells 5,025 Shares of Stock

Omnicell, Inc. (NASDAQ:OMCL) EVP Corey Manley sold 5,025 shares of the stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $43.22, for a total transaction of $217,180.50. Following the transaction, the executive vice president directly owned 112,783 shares in the company, valued at approximately $4,874,481.26. This represents a 4.27% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Omnicell Price Performance

Omnicell stock opened at $43.82 on Wednesday. Omnicell, Inc. has a 52-week low of $26.84 and a 52-week high of $55.00. The firm has a fifty day moving average of $37.71 and a 200-day moving average of $40.60. The firm has a market capitalization of $1.99 billion, a P/E ratio of 99.59, a PEG ratio of 1.12 and a beta of 0.96. The company has a quick ratio of 1.29, a current ratio of 1.50 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Tuesday, April 28th. The company reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.33 by $0.22. Omnicell had a net margin of 1.67% and a return on equity of 4.00%. The company had revenue of $309.88 million during the quarter, compared to analyst estimates of $304.02 million. During the same quarter in the prior year, the business earned $0.26 earnings per share. The business’s quarterly revenue was up 14.9% compared to the same quarter last year. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. As a group, analysts predict that Omnicell, Inc. will post 1.31 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in OMCL. Wellington Management Group LLP grew its holdings in Omnicell by 156.4% during the 4th quarter. Wellington Management Group LLP now owns 2,075,362 shares of the company’s stock worth $94,014,000 after acquiring an additional 1,265,818 shares in the last quarter. Millennium Management LLC acquired a new position in shares of Omnicell in the 3rd quarter valued at about $25,625,000. First Light Asset Management LLC acquired a new position in shares of Omnicell in the 1st quarter valued at about $16,351,000. Boston Partners acquired a new position in shares of Omnicell in the 4th quarter valued at about $20,805,000. Finally, WCM Investment Management LLC acquired a new position in shares of Omnicell in the 1st quarter valued at about $9,783,000. 97.70% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

OMCL has been the subject of a number of recent analyst reports. KeyCorp raised their price target on shares of Omnicell from $60.00 to $70.00 and gave the company an “overweight” rating in a report on Tuesday, April 28th. Benchmark reaffirmed a “buy” rating on shares of Omnicell in a report on Friday, March 13th. Zacks Research raised shares of Omnicell from a “hold” rating to a “strong-buy” rating in a report on Friday, May 1st. Bank of America raised shares of Omnicell from a “neutral” rating to a “buy” rating and set a $70.00 price target for the company in a report on Wednesday, February 4th. Finally, Wells Fargo & Company raised their price target on shares of Omnicell from $52.00 to $55.00 and gave the company an “overweight” rating in a report on Thursday, April 23rd. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $59.86.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.